Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.58 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320381 | 0.85 | SCN9A (0.62) | SCN9ASCN5A | |
| SCHEMBL320294 | 0.85 | SCN9A (0.62) | SCN9A | |
| SCHEMBL320536 | 0.84 | SCN9A (0.68) | SCN9ASCN5ASLC22A12 | |
| SCHEMBL318987 | 0.83 | SCN9A (0.62) | SCN9ASLC22A12 | |
| SCHEMBL320408 | 0.83 | SCN9A (0.57) | SCN9ASCN5A | |
| SCHEMBL319921 | 0.81 | SCN9A (0.57) | SCN9ASLC22A12 | |
| SCHEMBL16108028 | 0.79 | SCN9A (0.57) | SCN9ASCN5A | |
| SCHEMBL319733 | 0.79 | SCN9A (0.55) | SCN9A | |
| SCHEMBL319956 | 0.77 | SCN9A (0.63) | SCN9A | |
| SCHEMBL14891662 | 0.75 | SCN9A (0.62) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096558-B2 | N-sulfonylbenzamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9096558-B2 | N-sulfonylbenzamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9096558-B2 | N-sulfonylbenzamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| EP-2590957-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-12 | — | — | EP | disclosed |
| EP-2590957-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-12 | — | — | EP | disclosed |
| EP-2590957-A2 | CHEMICAL COMPOUNDS | Pfizer Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109696-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109696-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109696-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004714-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004714-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109696-A1 | Chemical Compounds | SCN1A, SCN7A, SCN1B | SCN9A 10/4885SCN5A 4/4885SLC22A12 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.